Stoke Therapeutics (STOK) Other Operating Expenses (2019 - 2025)
Stoke Therapeutics' quarterly Other Operating Expenses came in at -$218.7 million in Q4 2025, down 297.25% year-on-year from $110.9 million in Q4 2024, and down 386.75% quarter-over-quarter from -$44.9 million in Q2 2025.
Stoke Therapeutics has reported Other Operating Expenses for 3 years, with the latest figure at -$218.7 million in Q4 2025.
- For the quarter ending Q4 2025, Other Operating Expenses fell 297.25% year-over-year to -$218.7 million; the trailing twelve-month figure through Mar 2026 stood at -$263.6 million (down 460.87% YoY), and the FY2025 full-year result was -$218.7 million, changed N/A from the prior year.
- Other Operating Expenses for Q4 2025 stood at -$218.7 million, down from -$44.9 million in the prior quarter.
- The five-year high for Other Operating Expenses was $110.9 million in Q4 2024, with the low at -$218.7 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -218.72 Mn |
| Jun 30, 2025 | -44.93 Mn |
| Dec 31, 2024 | 110.88 Mn |
| Jun 30, 2024 | -37.82 Mn |
| Mar 31, 2024 | -34.59 Mn |
| Dec 31, 2019 | 1,000.00 |